Posted by Michael Wonder on 08 Dec 2022
NICE recommends Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus refractory (with or without resistance) to prior therapies
8 December 2022 - Livtencity is the first and only oral treatment that inhibits CMV specific UL97 protein kinase and its natural substrates.
Takeda UK today announced that NICE has issued its Final Appraisal Determination recommending Livtencity (maribavir) in line with its license, for the treatment of cytomegalovirus infection and/or disease that is refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant.
